

AD_____

Award Number:
W81XWH-06-1-0688

TITLE:
Assessment of GPR30, a Seven Transmembrane-spanning Estrogen Receptor, as an Oncogene

PRINCIPAL INVESTIGATOR:
Edward Joseph Filardo, PhD

CONTRACTING ORGANIZATION:
Rhode Island Hospital
Providence, RI 02903

REPORT DATE:
October 2009

TYPE OF REPORT:
Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

X Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 17-10-2009		2. REPORT TYPE Final		3. DATES COVERED (From - To) 18 Sep 2006 - 17 Sep 2009	
4. TITLE AND SUBTITLE Assessment of GPR30, a Seven Transmembrane-spanning Estrogen Estrogen Receptor, as an Oncogene				5a. CONTRACT NUMBER BC052936	
				5b. GRANT NUMBER W81XWH-06-1-0688	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Edward Joseph Filardo, PhD Email: edward_filardo@brown.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Rhode Island Hospital, Providence RI 02903				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Expression of the seven transmembrane-spanning receptor (7TMR), GPR30, in primary human breast tumors is positively associated with several tumor progression variables including extra mammary metastases (Filardo et al, 2006). Altered expression of 7TMRs is linked with a spectrum of disease phenotypes, including cancer, raising the possibility that GPR30 may function as an oncogene. Prior attempts to construct transgenic mice capable of expressing (HA-GPR30) transgenes under the transcriptional control of the mouse mammary tumor virus (MMTV) promoter failed. A second no cost extension was requested to construct mice with an HA-GPR30 transgene regulated by the whey acidic protein(WAP) promoter. These mice have recently been constructed and their genotypic and phenotypic analysis is underway.					
15. SUBJECT TERMS membrane receptor, estrogen, transgenic mice					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 6	19a. NAME OF RESPONSIBLE PERSON USAMRI
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusion.....	5
References.....	6

Introduction.

Breast tumor growth and survival is strongly influenced by estrogen and decisions regarding appropriate adjuvant therapy for patients with breast cancer are largely determined by the measurement of known estrogen receptors (ERs) in primary tumor or biopsy specimens. However, it has long been suspected that receptors other than the known estrogen receptors may promote estrogen action. Recent findings by our lab (1-4), and others (5-8), has shown that the seven transmembrane receptor (7TMR), GPR30, promotes specific estrogen binding and biochemical signaling and in addition is linked to tumor progression in man. To further address the role of GPR30 in experimental breast tumor biology, we have proposed to generate transgenic mice capable of overexpressing wild type or mutant GPR30 using the mammary gland specific promoter, whey acidic protein.

Body.

Work conducted during second no cost extension.

The second no cost extension term of this Concept award expired on October 31, 2009. The overall goal of the concept award was to generate transgenic mice that overexpressed wild-type or active GPR30 for the purpose of assessing the biological role of this newly appreciated membrane estrogen receptor in breast cancer. We successfully generated two founder mice (T6-1A and T6-2E) that contained a stably integrated wild-type hemagglutinin (HA)-tagged GPR30 transgene during that time frame and were unable to identify an active GPR30 allele (see Nov 1, 2006- Oct 31, 2007 progress report). Accordingly, we requested and were granted, a no-cost extension to further evaluate the expression of the transgene in these mice and to determine if there was an association with the development of mammary adenocarcinoma.

The work performed during the first no cost extension was limited to Task 1 of the original *Statement of Work*. No efforts were made to pursue the development of an active GPR30 allele as remaining monies did not allow. No salary support was drawn during the no-cost extension. Monies budgeted for the generation of GPR30 CAM mice were used, in part, to conduct breeding experiments that were designed to assess MMTV-HA-GPR30 transgene expression and potential malignancy in the mammary glands of nulliparous, parous and multiparous mice.

Two lines of mice (T6-1A and T6-2E) harboring stably integrated MMTV-HA-GPR30 transgenes were generated and evaluated for transgene expression. Despite the fact that the transgene was stably inherited in both lines of mice, the MMTV-HA-GPR30 transgene protein was not detected in either lineage and was not influenced by the pregnancy status of the mice. No indications of preneoplasia or malignancy were observed in any of the transgene positive mice. However, due to the fact that we did not measure transgene expression, we are unable to conclude whether GPR30 is involved in spontaneous mammary adenocarcinoma. (see Nov 1, 2007- Oct 31, 2008 progress report)

Salaries were covered entirely by Departmental Funds from Medicine at Rhode Island Hospital in both the first and second no cost extensions.

Task 1. To evaluate the impact of hyperexpressed wild-type GPR30 on mammary duct branching and predisposition for the development of invasive breast cancer.

Expression of WAP-HA-GPR30 in transgenic mouse strains.

A small amount of money \$5000 remained after the first no-cost extension for us to attempt to derive new mice containing a WAP-HA-GPR30 transgene. The transgene has been produced, the mice have been generated and we are currently in the process of analyzing the phenotype.

Key Research Elements.

None.

Reportable Outcomes.

None.

Conclusions.

None yet.

References.

1. Filardo EJ, Quinn JA, Bland KI and AR Frackelton Jr: 2000. Estrogen- induced activation of Erk-1 and Erk-2 requires the G-protein -coupled receptor homologue, GPR30, and occurs via transactivation of the EGF receptor through release of HB-EGF. *Mol Endocrinol.* 14: 1649-1660.
2. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI . 2002. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. *Mol Endocrinol.* 16: 70-84.
3. Thomas P, Pang Y, Filardo EJ, Dong J. 2005. Identity of a membrane estrogen receptor coupled to a G-protein in human breast cancer cells. *Endocrinol.* 146:624-632.
4. Filardo EJ, Graeber CT, Quinn, JA, Resnick, MB, Giri D, DeLellis, RA, Steinhoff, MA, Sabo E. 2006. Distribution of GPR30, a seven-membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathological determinants of tumor progression. *Clin Cancer Res.* 12: 6359-66.
5. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. 2005. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. *Science.* 307:1625-1630.

6. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Ando S, Maggiolini M. 2007. G α coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17 β -estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. *Cancer Res.* 67: 1859-1866
7. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Ando S, Maggiolini M. 2006. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17 β -estradiol and hydroxytamoxifen in endometrial cancer cells. *Mol Endocrinol.* 20:631-646
8. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, Prossnitz ER. 2007. GPR30: a novel indicator of poor survival for endometrial carcinoma. *Am J Obstet Gynecol.* 196: 386 e1-9
9. Clarke R. 1996. Animal models of breast cancer: their diversity and role in biomedical research. *Br J Cancer.* 39: 1-6.
10. Kordon EC. 2008. MMTV-induced pregnancy-dependent mammary tumors: early history and new perspectives. *J Mammary Biol Neopl.* 13: 289-297.

Appendices.

None.